Our mission is to develop better drugs, faster using technology.

We are developing drugs to treat the biggest medical challenges of our generation.

Our first drug VRG50635, a small molecule inhibitor of PIKfyve, has entered the clinic for amyotrophic lateral sclerosis (ALS). It was discovered by CONVERGE™, Verge’s all-in-human, AI-powered platform, moving from research to clinic in just four years. We are working on a dozen breakthrough opportunities on Parkinson`s Disease, Frontotemporal Dementia, and other devastating diseases with no effective treatments to date.

See our pipeline →

Verge Genomics - Video